Germany Daily Briefing

Bayer shed another 6.28% to 55.19 in Tuesday's session, extending a decline that has become one of the German equity market's defining chronic stories. The glyphosate/Roundup litigation in the US courts remains an open-ended liability; every adverse verdict, plaintiff settlement, or appellate reversal is treated as a catalyst for forced selling by ESG-constrained and risk-limit-driven institutional funds. At current levels Bayer trades at a fundamental discount versus European pharma/agro peers — the question is whether the litigation discount is now fully priced or whether it can deepen further.

Infineon Technology (IFNNY) dropped 3.15% to 63.87 as Chinese semiconductor market dynamics continued to weigh on the global chip supply chain. FAZ Finanzen reported that cheap Chinese chip alternatives are spreading negative sentiment across the European semiconductor space, creating pricing pressure downstream. For Infineon, which supplies automotive and industrial customers across the Asian supply chain, the China competition narrative is a structural margin threat that goes beyond cyclical inventory normalisation.

DW Business reported that Germany's long-standing framework of using China as an export market is being reweighted: Chinese import competition in autos, chemicals, and industrial equipment is now perceived as a greater threat than China is an opportunity for German exporters. This structural narrative realignment has direct implications for DAX-heavy exporters — Mercedes-Benz -1.48%, BASF exposure through chemicals, and the broader industrial names in the MDAX. The thesis reversal that was once theoretical is now visible in earnings guidance cuts.